Darrell J. Yamashiro, MD, PhD

Expertise in: 
Cancer Care
Board Certifications: 
Pediatric Hematology-Oncology, Pediatrics
Accepting New Patients
Treats Children
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

Cancer Care, Pediatric Liver Cancer, Hepatoblastoma, Angiogenesis, Wilm's Tumor, Pediatric Solid Tumors, Neuroblastoma

Academic Appointments

  • Associate Professor of Pathology & Cell Biology at CUMC
  • Associate Professor of Pediatrics at CUMC

Administrative Titles

  • Chief, Division of Hematology, Oncology, and Stem Cell Transplantation

Pediatric Oncology - NewYork-Presbyterian/Morgan Stanley Children's Hospital

Darrell J. Yamashiro, MD, PhD is a pediatric oncologist who specializes in the care of children with pediatric solid tumors, especially neuroblastoma, Wilms' tumor and other kidney tumors, and liver tumors such hepatoblastoma and hepatocellular carcinoma.

Although liver tumors in children are rare (they account for only one to two percent of childhood cancers), they can be very complex and require a multidisciplinary approach for optimal management. Dr. Yamashiro enjoys working as part of a team of physicians, nurse practitioners, nurses, social workers, child life specialists, and other dedicated healthcare professionals who deeply care about patients and who provide care with compassion and comfort.

Dr. Yamashiro also conducts basic science research. The latest advances in tumor genetics and the design of innovative therapies make this a very exciting time. For example, he and his team have done extensive research on the genetics of hepatoblastoma and developed mouse models, entering the phase of research where they are taking a personalized/precision medicine approach to this disease. They are also identifying novel genes that specifically target neuroblastoma-information that may be used to create targeted therapies.

Email: dy39@cumc.columbia.edu

Hospital Affiliations

  • NewYork-Presbyterian/Morgan Stanley Children's Hospital
  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • New York University School of Medicine
  • Internship: Children's Hospital of Philadelphia
  • Residency: Children's Hospital of Philadelphia
  • Fellowship: Children's Hospital of Philadelphia

Board Certifications

  • Pediatric Hematology-Oncology
  • Pediatrics
NY Top Doctor

Research

Grants

QUANTUM COLLABORATION AWARD (Private)

Aug 15 2018 - Dec 15 2023

PRECISION MEDICINE PROGRAM FOR CHILDREN WITH HIGH-RISK CANCERS (Private)

Jan 1 2016 - Dec 31 2019

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2019

PRECISION MEDICINE PROGRAM FOR CHILDREN WITH HIGH-RISK CANCERS (Private)

Jan 1 2016 - Dec 31 2018

COLUMBIA UNIVERSITY DEVELOPMENTAL THERAPEUTICS PROGRAM: STRIVING FOR EXCELLENCE (Private)

Jan 1 2014 - Dec 31 2018

PRECISION MEDICINE PROGRAM FOR CHILDREN WITH HIGH-RISK CANCERS (Private)

Jan 1 2016 - Sep 30 2018

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2018

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2017

SOHN COLLABORATIVE FOR PEDIATRIC CANCER RESEARCH (Private)

Apr 22 2014 - Dec 31 2016

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2016

SOHN COLLABORATIVE FOR PEDIATRIC CANCER RESEARCH (Private)

Apr 22 2014 - Apr 21 2016

PEDIATRIC ONCOLOGY STUDENT TRAINING (POST) PROGRAM (Private)

Apr 1 2015 - Mar 31 2016

IDENTIFICATION OF TFAP4 (TRANSCRIPTION FACTOR AP-4/ACTIVATING ENHANCER BINDING PROTEIN) AS A POTENTIAL MASTER REGULATOR/SYNTHETIC LETHAL GENE OF MYCN AMPLIFIED NEUROBLASTOMA (Private)

Jul 1 2013 - Jul 1 2015

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2015

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2014

VEGF BLOCKADE AND ALTERNATIVE ANGIOGENIC PATHWAYS IN NEUROBLASTOMA (Federal Gov)

Apr 10 2008 - Jan 31 2014

USING CONTRAST ENHANCED ULTRASOUND TO ASSESS THE EFFICACY OF ADT INHIBITION AS A RADIOSENSITIZER IN EXPERIMENTAL NEUROBLASTOMA (Private)

May 1 2013 - Aug 31 2013

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2013

PEDIATRIC CANCER RESEARCH FOUNDATION (Private)

Jul 1 2005 - Jun 30 2013

NOVEL MICROBUBBLE-BASED GENE DELIVERY VEHICLES TARGETING SOL ID TUMORS (Private)

Jul 1 2009 - Jan 31 2011

THE ROLE OF NOTCH SIGNALING IN NEUROBLASTOMA ANGIOGENESIS (Private)

Jul 1 2007 - Jun 30 2010

Selected Publications

Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe-Chiweshe A, Connolly EP, Kandel JJ, Rajbhandari P, Silva JM, **Califano A, **Yamashiro DJ. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma. Oncogene. 2018. Epub 2018/06/09. doi: 10.1038/s41388-018-0326-9. PubMed PMID: 29880876.

Tavana O, Li D, Dai C, Lopez G, Banerjee D, Kon N, Chen C, Califano A, Yamashiro DJ, Sun H, Gu W. HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma. Nat Med. 2016. doi: 10.1038/nm.4180. PubMed PMID: 27618649.

Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Med. 2016;8(1):133. doi: 10.1186/s13073-016-0389-6. PubMed PMID: 28007021; PMCID: PMC5180407.

Dela Cruz FS, Diolaiti D, Turk AT, Rainey AR, Ambesi-Impiombato A, Andrews SJ, Mansukhani MM, Nagy PL, Alvarez MJ, Califano A, Forouhar F, Modzelewski B, Mitchell CM, Yamashiro DJ, Marks LJ, Bender JL, Kung AL. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016;8(1):116. doi: 10.1186/s13073-016-0366-0. PubMed PMID: 27799065.

Jani A, Shaikh F, Barton S, Willis C, Banerjee D, Mitchell J, Hernandez SL, Hei T, Kadenhe-Chiweshe A, **Yamashiro DJ, **Connolly EP. High-Dose, Single-Fraction Irradiation Rapidly Reduces Tumor Vasculature and Perfusion in a Xenograft Model of Neuroblastoma. Int J Radiat Oncol Biol Phys. 2016;94(5):1173-80. doi: 10.1016/j.ijrobp.2015.12.367. PubMed PMID: 26907918.

Banerjee D, Hernandez SL, Garcia A, Kangsamaksin T, Sbiroli E, Andrews J, Forrester LA, Wei N, Kadenhe-Chiweshe A, Shawber CJ, Kitajewski JK, **Kandel JJ, **Yamashiro DJ. Notch suppresses angiogenesis and progression of hepatic metastases. Cancer Res. 2015;75(8):1592-1602. PMID: 25744722; PMCID: PMCPMC4401639.